

COVID-19 Vaccination Progress: United States


Christine Hahn, MD
Idaho Division of Public Health
CVAC 2/5/2021



IDAHO DEPARTMENT OF
HEALTH & WELFARE




Total Doses Administered Reported to the CDC by State/Territory and for Selected Federal Entities per 100,000



COVID-19 VACCINE ROLLOUT in the U.S.: DISTRIBUTION



Total Doses Distributed Reported to the CDC by State/Territory and for Selected Federal Entities per 100,000 population





Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021

Elizabeth M. Painter, PhD¹; Emily N. Ussery, PhD¹; Anita Patel, PharmD¹; Michael L. Moulia, MPH^{1,3}; Lynn Gibbs Scharf, MPH¹; Michael Lynch, MD¹; Michael B. Herlihy, MD¹; Bhavini Patel Murthy, MD¹; LaTrece Q. Harris, MPH¹; Annemarie Wasley, ScD¹; Dale A. Bricker, PhD¹

In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) were authorized for emergency use in the United States for the prevention of coronavirus disease 2019 (COVID-19).^{*} Because of limited initial vaccine supply, the Advisory Committee on Immunization Practices (ACIP) prioritized vaccination of health care personnel[†] and residents and staff members of long-term care facilities (LTCF) during the first phase of the U.S. COVID-19 vaccination program (1). Both vaccines require 2 doses to complete the series. Data on vaccines administered during December 14, 2020–January 14, 2021, and reported to CDC by January 26, 2021, were analyzed to describe demographic characteristics,


rapid detection of COVID-19 program vaccine is successful those at high risk for outcomes non-Hispanic Hispanic Data on United States reported to

TABLE. Demographic characteristics of persons initiating COVID-19 vaccination — United States, December 14, 2020–January 14, 2021*

Characteristic (no. [%] with available information)	No. (%) [†]
Overall	12,928,749 (100.0)
Sex (12,537,841 [97.0])	
Male	4,639,073 (37.0)
Female	7,898,768 (63.0)
Age group,[§] yrs (12,924,116 [99.9])	
<18	4,837 (<0.1)
18–29	1,433,086 (11.1)
30–39	2,207,222 (17.1)
40–49	2,175,305 (16.8)
50–64	3,350,610 (25.9)
65–74	1,732,522 (13.4)
≥75	2,020,534 (15.6)
Race/Ethnicity[¶] (6,706,697 [51.9])	
White, non-Hispanic	4,047,795 (60.4)
Hispanic/Latino	773,858 (11.5)
Black, non-Hispanic	359,934 (5.4)
Asian, non-Hispanic	405,227 (6.0)
AI/AN, non-Hispanic	134,127 (2.0)
NH/PI, non-Hispanic	20,585 (0.3)
Multiple/Other, non-Hispanic**	965,171 (14.4)

Abbreviations: AI/AN = American Indian/Alaska Native; COVID-19 = coronavirus disease 2019; NH/PI = Native Hawaiian or Other Pacific Islander.



Administration Priorities COVID-19

BRIEFING ROOM

FACT SHEET: President Biden Announces Increased Vaccine Supply, Initial Launch of the Federal Retail Pharmacy Program, and Expansion of FEMA Reimbursement to States


FEBRUARY 02, 2021 • STATEMENTS AND RELEASES

States, Tribes, and territories, and Americans will see the benefits of these new steps.

As the U.S. surpasses 26 million additional steps today to combat the COVID-19 pandemic, the White House today announced additional steps to increase vaccine supply to states, Tribes, and territories, to help turn vaccines into shots starting next week, the federal government will launch and select pharmacies in their communities.

These new steps will help deliver 100 million shots in 100 days in the coming weeks.

- Expanding Vaccine Supply
 - Increase in doses sent to states, Tribes, and territories each week
- Launching First Phase of the Federal Retail Pharmacy Program
 - Starting Feb 11
 - Select pharmacies
- Increasing Reimbursement to States
 - FEMA directed to reimburse for National Guard and emergency costs, PPE, and other costs



INNOVATION

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Johnson & Johnson intends to distribute vaccine to the U.S. government immediately following authorization, and expects to supply 100 million doses to the U.S. in the first half of 2021

NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson announced that Janssen Biotech, Inc., has submitted an application (FDA) requesting Emergency Use Authorization (EUA) for its investigational COVID-19 vaccine candidate. The Company's EUA submission is based on data from its Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational vaccine is safe and effective, and key secondary endpoints. The Company expects to have product authorization.



Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Janssen Biotech Inc.'s COVID-19 Vaccine Candidate

The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 26, 2021, to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Janssen Biotech Inc.

"A public discussion by the advisory committee members about the data submitted in support of safety and effectiveness of Janssen Biotech Inc.'s COVID-19 vaccine will help ensure that the public has a clear understanding of the scientific data and information that FDA will evaluate in order to make a decision about whether to authorize this vaccine," said Acting FDA Commissioner Janet Woodcock, M.D. "The FDA remains committed to keeping the public informed about our evaluation of the data for COVID-19 vaccines, so that the American public and medical community have trust and confidence in FDA-authorized vaccines."